Pharma Giants AstraZeneca and GSK Tap Onco-Innovations’ Causal AI to Sharpen Cancer Trial Predictions

Onco-Innovations has locked down collaboration agreements with two of the world’s largest pharmaceutical companies within days, underscoring the race to apply artificial intelligence to oncology drug development. The biotech’s subsidiary Inka Health will power both partnerships, combining causal AI and machine learning to tackle a perennial industry challenge: predicting whether a cancer therapy will actually work in patients.

The first deal, announced Tuesday, teams Inka Health with AstraZeneca under the PROmAI program. The partners are pooling molecular, clinical and imaging data from anonymized research databases, using causal AI techniques that identify genuine cause-and-effect relationships rather than mere statistical correlations. Thomas O’Shaughnessy, CEO of Onco-Innovations, said the approach should speed up insights and reduce uncertainty in drug development. Causal models, he argued, go beyond standard machine learning by uncovering the mechanisms behind treatment responses rather than just spotting patterns.

Separately, Onco-Innovations inked a contract with GlaxoSmithKline focused on real-world patient data. Here the emphasis is on bridging the gap between controlled clinical trials and outcomes in the broader population. Inka Health applies machine learning to anonymized datasets so that trial results can be extrapolated more reliably to everyday medical practice. Both arrangements feed into the company’s proprietary SynoGraph platform, which is now gaining traction as big pharma looks for data-driven ways to strengthen regulatory submissions.

Should investors sell immediately? Or is it worth buying Onco-Innovations?

While the partnerships validate its analytical tools, Onco-Innovations is also pushing forward its own drug pipeline. Nucro-Technics, a contract research firm, has begun developing specialized analytical methods for the company’s lead compound, the PNKP inhibitor A83B4C63. The current round of preclinical animal studies is designed to generate dosing data and pave the way for GLP-compliant toxicology tests that are required before human trials can begin.

On the clinical front, the company is targeting a Phase-1 study in 2026 for advanced cancers characterized by PTEN or SHP-1 deficiency. To take advantage of generous research incentives, Onco-Innovations has set up an Australian subsidiary and signed agreements with RDI Partners and Avance Clinical. Australia offers tax rebates of up to 43.5% on qualifying R&D expenditure, a critical factor for a cash-conscious biotech. At the same time, management is preparing a cross-listing on a US exchange, expected to be completed within the current year, to tap a broader investor base.

The market has responded enthusiastically to the flurry of news. Onco-Innovations shares have surged nearly 89% over the past 30 days, though at €0.70 they remain 53% below the 52-week high. The stock’s annualized volatility stands at roughly 132%, underlining the speculative nature of the investment. With the Phase-1 trial and the US listing both slated for 2026, the next concrete catalysts are likely to test whether the recent rally can be sustained.